Page last updated: 2024-12-08
sulfachlorpyrazine
Description
Research Excerpts
Clinical Trials
Roles
Classes
Pathways
Study Profile
Bioassays
Related Drugs
Related Conditions
Protein Interactions
Research Growth
Market Indicators
Description
sulfachlorpyrazine : A sulfonamide containing a 5-chloropyrazin-2-yl moiety linked to the amide nitrogen; principally used in veterinary medicine. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]
Cross-References
| ID Source | ID |
|---|---|
| PubMed CID | 164867 |
| CHEBI ID | 145370 |
| SCHEMBL ID | 6752479 |
| MeSH ID | M0144511 |
Synonyms (19)
| Synonym |
|---|
| AC-7628 |
| sulfachlorpyrazine |
| 1672-91-9 |
| CHEBI:145370 |
| 4-amino-n-(5-chloropyrazin-2-yl)benzenesulfonamide |
| 4-amino-n-(5-chloropyrazin-2-yl)benzene-1-sulfonamide |
| sulphachloropyrazine |
| 96r84uz2xa , |
| unii-96r84uz2xa |
| 4-amino-n-(5-chloropyrazinyl)benzenesulfonamide |
| benzenesulfonamide, 4-amino-n-(5-chloropyrazinyl)- |
| benzenesulfonamide, 4-amino-n-(5-chloro-2-pyrazinyl)- |
| 4-amino-n-(5-chloropyrazinyl)-benzenesulfonamide |
| SCHEMBL6752479 |
| AKOS025402285 |
| F1905-8633 |
| DTXSID50937296 |
| 4-amino-n-(5-chloropyrazin-2(1h)-ylidene)benzene-1-sulfonamide |
| Q27271921 |
Research Excerpts
Dosage Studied
| Excerpt | Relevance | Reference |
|---|---|---|
| " Therefore, the suggested withdrawal period for SPZ-DVD suspension should be 7 days after dosing for seven successive days." | ( Determination of sulphachloropyrazine-diaveridine residues by high performance liquid chromatography in broiler edible tissues. Bu, S; Li, Y, 2016) | 0.43 |
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
Drug Classes (1)
| Class | Description |
|---|---|
| sulfonamide | An amide of a sulfonic acid RS(=O)2NR'2. |
| [compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
Research
Studies (12)
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 1 (8.33) | 18.7374 |
| 1990's | 1 (8.33) | 18.2507 |
| 2000's | 2 (16.67) | 29.6817 |
| 2010's | 7 (58.33) | 24.3611 |
| 2020's | 1 (8.33) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
Market Indicators
Research Demand Index: 30.59
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.
| This Compound (30.59) All Compounds (24.57) |
Study Types
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 15 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||